Weizenwampe

2004;104:1287–91.
    22Negrean et al. Am J Clin Nutr 2007;85:1236–43.
    23Sarwar N, Aspelund T, Eiriksdottir G et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLos Med 2010 May 25;7(5):e1000278.
    24International Expert Committee. International Expert Committee report on the role of the HbA1c assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327–44.
    25Khaw KT, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Brit Med J 2001 Jan 6;322(7277):15–8.
    26Gerstein HC, Swedberg K, Carlsson J et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008 Aug 11;168(15):1699–704.
    27Khaw et al. Brit Med J 2001 Jan 6;322(7277):15–8.
    28Swami-Mruthinti S, Shaw SM, Zhao HR et al. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr Eye Res 1999 Jun;18(6):423–9.
    29Rowe NG, Mitchell PG, Cumming RG, Wans JJ. Diabetes, fasting blood glucose and age-related cataract: the Blue Mountains Eye Study. Opththalmic Epidemiol 2000 Jun;7(2):103–14.
    30Kataraktoperation: Risikominderung einer Blutung bei oraler Antikoagulation. Deutsches Ärzteblatt 10. Januar 2005;102(1-2): A-58. Zitiert nach: http://www.aerzteblatt.de/archiv/44945
    31Sperduto RD, Seigel D. Senile lens and senile macular changes in a population-based sample. Am J Opththalmol 1980 Jul;90(1):86–91.
    32Stitt et al. Mol Med 1997;3:617–27.
    33Ishibashi T, Kawaguchi M, Sugimoto K et al. Advanced glycation end product-mediated matrix metalloproteinase-9 and apoptosis via reninangiotensin system in type 2 diabetes. J Atheroscler Thromb 2010; 17(6):578–89.
    34Vlassara H, Torreggiani M, Post JB et al. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl 2009 Dec;(114):S3–11.
    10. Kapitel
    1Stalenhoef AF, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 2008;19:355–61.
    2Lamarche B, Lemieux I, Després JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999 Sep;25(3):199–211.
    3Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003;31:1066–9.
    4De Graaf J, Hak-Lemmers HL, Hectors MP et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991 Mar-Apr;11(2):298–306.
    5Younis N, Sharma R, Soran H et al. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 2008 Aug;19(4):378–84.
    6Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999 Apr 20;99(15):1959–64.
    7Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002;106:2137–42.
    8Stalenhoef et al. Curr Opin Lipidol 2008;19:355–61.
    9Ford ES, Li C, Zhgao G et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009 Mar 23;169(6):572–8.
    10Superko HR. Beyond LDL cholesterol reduction. Circulation 1996 Nov 15;94(10):2351–4.
    11Lemieux I, Couillard C, Pascot A et al. The small, dense LDL phenotype as a correlate of postprandial lipemia in men. Atherosclerosis 2000;153:423–32.
    12Nordestgaard BG, Benn M, Schnohr P et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007 Jul 18;298(3):299–308.
    13Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002 Oct 17;90(8A):48i–54i.
    14Otvos JD, Jeverajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002 Oct 17;90(8A):22i–9i.
    15Parks EJ, Hellerstein MK. Carbohydrate-induced